Table 2.
Multivariate proportional hazards analyses for the risk of recurrence on selected peak clusters, before (model 1, subpopulation) and after (model 3, total study population) adjustment for relevant clinical parameters, and on relevant clinical parameters solely (model 2, total study population)
| Parameter | Model 1—peak clusters | Model 2—clinical parameters | Model 3—combined | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | (95% CI) | P value | HR | (95% CI) | P value | HR | (95% CI) | P value | |
| Peak cluster | |||||||||
| m/z 3073 | 3.17 | (2.03–4.96) | <0.001 | 2.48 | (1.78–3.48) | <0.001 | |||
| m/z 3274 | 10.18 | (1.99–52.01) | 0.005 | 11.71 | (2.05–66.90) | 0.006 | |||
| m/z 4405 | 0.02 | (0.01–0.25) | 0.003 | 0.01 | (0.01–0.17) | 0.001 | |||
| m/z 7973 | 0.05 | (0.01–0.48) | 0.010 | 0.24 | (0.03–1.78) | 0.160 | |||
| Treatment | |||||||||
| CONV | 1 | – | – | 1 | – | – | |||
| HD | 1.59 | (0.86–2.95) | 0.140 | 2.48 | (1.24–4.98) | 0.011 | |||
| Age | |||||||||
| <40 years | 1 | – | – | 1 | – | – | |||
| ≥40 years | 0.44 | (0.22–0.88) | 0.021 | 0.35 | (0.16–0.74) | 0.006 | |||
| No. of LN+ | |||||||||
| ≥10 | 1 | – | – | 1 | – | – | |||
| 4–9 | 0.44 | (0.23–0.84) | 0.012 | 0.37 | (0.19–0.72) | 0.003 | |||
| PR status | |||||||||
| PR(−) | 1 | – | – | 1 | – | – | |||
| PR(+) | 0.40 | (0.22–0.73) | 0.003 | 0.28 | (0.14–0.55) | < 0.001 | |||
CONV conventional dose arm, HD high-dose arm, LN+ number of positive lymph nodes, PR progesterone receptor status positive (+) and negative (−)